Respiratory syncytial virus vial.
Manjuru | Stocks | Getty Images
PfizerRespiratory syncytial virus vaccine offers protection to older adults two whole seasons The company announced Thursday that it is conducting an ongoing late-stage clinical trial to study the disease.
The vaccine’s efficacy dropped slightly compared with levels of protection after one RSV season, but new data suggests the vaccine generally provides long-lasting protection in adults 60 and older who more vulnerable Serious illness caused by RSV.this emission Pfizer’s vaccine (called Abrysvo) and another RSV vaccine GSK Last year proved to be a boon for both companies, with the vaccine racking up hundreds of millions of dollars in sales in just half a year on the market.
In the second quarter, a single dose of the Pfizer vaccine was 77.8% effective against more severe lower respiratory illness with three or more symptoms, down from 88.9% at the end of the first quarter. These symptoms include wheezing, shortness of breath, rapid and shallow breathing, and production of mucus.
The vaccine was about 55.7% effective against less severe disease with two or more symptoms after the second season, according to preliminary data on more than 37,000 participants in the northern and southern hemispheres. After one RSV season, the vaccine was 66.7% effective against this condition.
Pfizer noted that following the second RSV season, the vaccine showed consistent efficacy against RSV A and RSV B, the two main subtypes of the virus. For patients with more severe lower respiratory tract disease, the vaccine was 80% or more effective against each type.
After two seasons, patients reported no new adverse events.
The results were released ahead of Thursday’s meeting of a Centers for Disease Control and Prevention advisory panel that will consider whether older adults should get the RSV vaccine every year or every other year.
Analysts don’t expect the committee to make its final recommendations until June — a decision that could have serious consequences for modern,Right now Hope to launch Also got my own RSV vaccination this year.
Jefferies analyst Michael Yee said in a report last week that the company sees a 50% to 70% chance that the panel will recommend annual vaccinations, which would give Moderna “at least as much” as Pfizer and GlaxoSmithKline. Considerable market share.” He noted that a biennial recommendation based on two seasons of GSK data would “reduce Moderna’s competitive position.”
In older adults, GlaxoSmithKline shot shows cumulative Effectiveness 67.2% Preventing lower respiratory tract disease during both RSV seasons. By comparison, one season after the virus outbreak, the rate was 82.6%.
GSK’s vaccine sales last year were about 1.2 billion pounds ($1.5 billion). At the same time, Pfizer’s vaccine has also been approved for expectant mothers, which can pass protection to their children, with revenue in 2023 of approximately $890 million.
According to the CDC, RSV kills 6,000 to 10,000 older adults each year and causes 60,000 to 160,000 hospitalizations.
Don’t miss these stories from CNBC PRO:
About The Author
